Cargando…
Immunologic aspect of ovarian cancer and p53 as tumor antigen
Ovarian cancer represents the fifth leading cause of death from all cancers for women. During the last decades overall survival has improved due to the use of new chemotherapy schedules. Still, the majority of patients die of this disease. Research reveals that ovarian cancer patients exhibit signif...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1243238/ https://www.ncbi.nlm.nih.gov/pubmed/16164749 http://dx.doi.org/10.1186/1479-5876-3-34 |
_version_ | 1782125629901111296 |
---|---|
author | Nijman, HW Lambeck, A van der Burg, SH van der Zee, AGJ Daemen, T |
author_facet | Nijman, HW Lambeck, A van der Burg, SH van der Zee, AGJ Daemen, T |
author_sort | Nijman, HW |
collection | PubMed |
description | Ovarian cancer represents the fifth leading cause of death from all cancers for women. During the last decades overall survival has improved due to the use of new chemotherapy schedules. Still, the majority of patients die of this disease. Research reveals that ovarian cancer patients exhibit significant immune responses against their tumor. In this review the knowledge obtained thus far on the interaction of ovarian cancer tumor cells and the immune system is discussed. Furthermore the role of p53 as tumor antigen and its potential role as target antigen in ovarian cancer is summarized. Based on the increased knowledge on the role of the immune system in ovarian cancer major improvements are to be expected of immunotherapy based treatment of this disease. |
format | Text |
id | pubmed-1243238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-12432382005-10-07 Immunologic aspect of ovarian cancer and p53 as tumor antigen Nijman, HW Lambeck, A van der Burg, SH van der Zee, AGJ Daemen, T J Transl Med Review Ovarian cancer represents the fifth leading cause of death from all cancers for women. During the last decades overall survival has improved due to the use of new chemotherapy schedules. Still, the majority of patients die of this disease. Research reveals that ovarian cancer patients exhibit significant immune responses against their tumor. In this review the knowledge obtained thus far on the interaction of ovarian cancer tumor cells and the immune system is discussed. Furthermore the role of p53 as tumor antigen and its potential role as target antigen in ovarian cancer is summarized. Based on the increased knowledge on the role of the immune system in ovarian cancer major improvements are to be expected of immunotherapy based treatment of this disease. BioMed Central 2005-09-15 /pmc/articles/PMC1243238/ /pubmed/16164749 http://dx.doi.org/10.1186/1479-5876-3-34 Text en Copyright © 2005 Nijman et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Nijman, HW Lambeck, A van der Burg, SH van der Zee, AGJ Daemen, T Immunologic aspect of ovarian cancer and p53 as tumor antigen |
title | Immunologic aspect of ovarian cancer and p53 as tumor antigen |
title_full | Immunologic aspect of ovarian cancer and p53 as tumor antigen |
title_fullStr | Immunologic aspect of ovarian cancer and p53 as tumor antigen |
title_full_unstemmed | Immunologic aspect of ovarian cancer and p53 as tumor antigen |
title_short | Immunologic aspect of ovarian cancer and p53 as tumor antigen |
title_sort | immunologic aspect of ovarian cancer and p53 as tumor antigen |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1243238/ https://www.ncbi.nlm.nih.gov/pubmed/16164749 http://dx.doi.org/10.1186/1479-5876-3-34 |
work_keys_str_mv | AT nijmanhw immunologicaspectofovariancancerandp53astumorantigen AT lambecka immunologicaspectofovariancancerandp53astumorantigen AT vanderburgsh immunologicaspectofovariancancerandp53astumorantigen AT vanderzeeagj immunologicaspectofovariancancerandp53astumorantigen AT daement immunologicaspectofovariancancerandp53astumorantigen |